Nevada’s Vetoed Insulin Cost Transparency Bill Returns, as California Advances Several Pricing Measures Post author:Sam Post published:June 5, 2017 Post category:Drug Industry Daily Lawmakers in Nevada and California continue to target drugmakers in health care proposals. Source: Drug Industry Daily You Might Also Like FDA Eases Expiration Date Requirements for Repackaged Solid Oral Dosage Drugs August 8, 2017 PTAB Begins IPR Review of Two Sanofi Patents December 20, 2017 Paclitaxel-Coated Devices Don’t Carry Excess Mortality Risk, FDA Says July 12, 2023